S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

实时更新: Bayer AG [BAYN.DE]

交易所: XETRA 工业: Pharmaceuticals, Biotechnology & Life Sciences
最后更新时间26 Apr 2024 @ 23:39

1.88% 27.40

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:39):

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments...

Stats
今日成交量 4.69M
平均成交量 4.77M
市值 26.92B
EPS €0 ( 2024-03-04 )
下一个收益日期 ( €2.32 ) 2024-05-14
Last Dividend €2.40 ( 2023-05-02 )
Next Dividend €0 ( N/A )
P/E -9.16
ATR14 €0.0150 (0.05%)

音量 相关性

長: -0.09 (neutral)
短: -0.38 (neutral)
Signal:(49.906) Neutral

Bayer AG 相关性

10 最正相关
10 最负相关

你知道吗?

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。

相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Bayer AG 相关性 - 货币/商品

The country flag 0.23
( neutral )
The country flag 0.20
( neutral )
The country flag 0.00
( neutral )
The country flag 0.11
( neutral )
The country flag 0.00
( neutral )
The country flag -0.27
( neutral )

Bayer AG 财务报表

Annual 2023
营收: €47.64B
毛利润: €27.89B (58.54 %)
EPS: €-2.99
FY 2023
营收: €47.64B
毛利润: €27.89B (58.54 %)
EPS: €-2.99
FY 2022
营收: €50.74B
毛利润: €30.87B (60.84 %)
EPS: €4.22
FY 2021
营收: €44.08B
毛利润: €27.27B (61.85 %)
EPS: €1.018

Financial Reports:

No articles found.

Bayer AG Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€2.40
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)
€0
(N/A)

Bayer AG Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.23 - low (7.68%) | Divividend Growth Potential Score: 2.19 - Decrease likely (56.20%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend €1.279 2000-05-02
Last Dividend €2.40 2023-05-02
Next Dividend €0 N/A
Payout Date 0000-00-00
Next Payout Date N/A
# dividends 25 --
Total Paid Out €43.29 --
Avg. Dividend % Per Year 0.00% --
Score 1.56 --
Div. Sustainability Score 3.23
Div.Growth Potential Score 2.19
Div. Directional Score 2.71 --
Next Divdend (Est)
(2025-03-31)
€2.45 Estimate 3.12 %
Dividend Stability
0.25 Very Poor
Dividend Score
1.56
Pay Frequency
Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
PER.DE Ex Dividend Knight 2023-07-05 Annually 0 0.00%
BAYN.DE Ex Dividend Junior 2023-05-02 Annually 0 0.00%
HNR1.DE Ex Dividend Junior 2023-05-04 Annually 0 0.00%
SCT.DE Ex Dividend Knight 2023-07-27 Annually 0 0.00%
COK.DE Ex Dividend Junior 2023-06-15 Annually 0 0.00%
KRN.DE Ex Dividend Knight 2023-05-24 Annually 0 0.00%
185.DE Ex Dividend Junior 2023-08-07 Quarterly 0 0.00%
TRVC.DE Ex Dividend Junior 2023-08-04 Quarterly 0 0.00%
DYH.DE Ex Dividend Knight 2023-11-14 Quarterly 0 0.00%
MUX.DE Ex Dividend Junior 2023-07-11 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM-0.06171.500-1.235-1.852[0 - 0.5]
returnOnAssetsTTM-0.02381.200-0.795-0.954[0 - 0.3]
returnOnEquityTTM-0.08161.500-2.02-3.03[0.1 - 1]
payoutRatioTTM-0.809-1.000-8.098.09[0 - 1]
currentRatioTTM1.2590.8008.706.96[1 - 3]
quickRatioTTM0.7840.800-0.0946-0.0757[0.8 - 2.5]
cashRatioTTM0.2011.50010.0010.00[0.2 - 2]
debtRatioTTM0.355-1.5004.08-6.11[0 - 0.6]
interestCoverageTTM0.5951.000-0.891-0.891[3 - 30]
operatingCashFlowPerShareTTM4.852.008.3810.00[0 - 30]
freeCashFlowPerShareTTM2.052.008.9710.00[0 - 20]
debtEquityRatioTTM1.332-1.5004.67-7.01[0 - 2.5]
grossProfitMarginTTM0.5851.0003.583.58[0.2 - 0.8]
operatingProfitMarginTTM0.03331.000-1.333-1.333[0.1 - 0.6]
cashFlowToDebtRatioTTM0.1091.000-0.507-0.507[0.2 - 2]
assetTurnoverTTM0.3860.800-0.759-0.607[0.5 - 2]
Total Score3.23

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM-9.151.000-1.0260[1 - 100]
returnOnEquityTTM-0.08162.50-1.297-3.03[0.1 - 1.5]
freeCashFlowPerShareTTM2.052.009.3210.00[0 - 30]
dividendYielPercentageTTM8.761.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.852.008.3810.00[0 - 30]
payoutRatioTTM-0.8091.500-8.098.09[0 - 1]
pegRatioTTM0.1171.500-2.550[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1001.00010.000[0.1 - 0.5]
Total Score2.19

Bayer AG

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

关于 实时信号

此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。

实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。